At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 264 enrolled
Drug / intervention
LBR-101 High Dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Dec 27, 2013·Updated Dec 9, 2021
In Brief
A Phase 2 clinical trial evaluating LBR-101 High Dose, LBR-101 Low Dose, and 1 other intervention for Chronic Migraine. Completed, enrolled 264 participants across 57 sites.
Detailed Summary
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartJan 2014
Primary CompletionFeb 2015
Study CompletionMar 2015
TodayJul 2026
First PostedDec 27, 2013
Enrollment StartJan 31, 2014
Primary CompletionFeb 28, 2015
Study CompletionMar 31, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.5 years ago
Interventions
LBR-101 High Dosedrug
Subcutaneously Administered LBR-101 Monthly x 3
LBR-101 Low Dosedrug
Subcutaneously Administered LBR-101 Monthly x 3
Placebodrug
Subcutaneously Administered Placebo (Vehicle) Monthly x 3